Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 324
  • Home
  • Print this page
  • Email this page
Year : 2017  |  Volume : 12  |  Issue : 1  |  Page : 60-66

In silico designing of a new cysteine analogue of hirudin variant 3 for site specific PEGylation

1 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
2 Molecular Medicine Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
3 Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
4 Rasoul Akram Medical Center, Iran University of Medical Sciences, Tehran, Iran
5 Biotechnology Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
6 Thrombosis and Homeostasis Research Center, Imam Khomeni Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Hasan Mirzahoseini
Biotechnology Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1735-5362.199048

Rights and Permissions

Hirudin is an anticoagulant agent of the salivary glands of the medicinal leech. Recombinant hirudin (r-Hir) displays certain drawbacks including bleeding and immunogenicity. To solve these problems, cysteine-specific PEGylation has been proposed as a successful technique. However, proper selection of the appropriate cysteine residue for substitution is a critical step. This study has, for the first time, used a computational approach aimed at identifying a single potential PEGylation site for replacement by cysteine residue in the hirudin variant 3 (HV3). Homology modeling (HM) was performed using MODELLER. All non-cysteine residues of the HV3 were replaced with the cysteine. The best model was selected based on the results of discrete optimized protein energy score, PROCHECK software, and Verify3D. The receptor binding was investigated using protein-protein docking by ClusPro web tool which was then visualized using LigPlot+ software and PyMOL. Finally, multiple sequence alignment (MSA) using ClustalW software and disulfide bond prediction were performed. According to the results of HM and docking, Q33C, which was located on the surface of the protein, was the best site for PEGylation. Furthermore, MSA showed that Q33 was not a conserved residue and LigPlot+ software showed that it is not involved in the hirudin-thrombin binding pocket. Moreover, prediction softwares established that it is not involved in disulfide bond formation. In this study, for the first time, the utility of the in silico approach for creating a cysteine analogue of HV3 was introduced. Our study demonstrated that the substitution of Q33 by cysteine probably has no effect on the biological activity of the HV3. However, experimental analyses are required to confirm the results.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded252    
    Comments [Add]    

Recommend this journal